$695 | Single User
$1395 | Global License

Physician Views: Sanofi secures EU approval for its multiple sclerosis treatment Lemtrada – how will neurologists use it?
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 01 Sep 2013 | 66 | In Stock
Related Topics: Lemtrada

Introduction

Scope


With Sanofi securing European approval for its multiple sclerosis therapy Lemtrada last week, neurologists in the region have at their disposal a new option in the treatment armoury.



A number of key opinion leaders (KOLs) have previously argued to FirstWord that Lemtrada is the most efficacious MS therapy available, but that usage will be limited by a more prominent safety profile versus other treatments - see FirstWord Therapy Trends: Multiple Sclerosis - KOL Insight.



This has driven some KOLs to suggest that Lemtrada could be used primarily as a last line of treatment, although others have said that given its potential to 'switch off' relapses for a year or two after initial administration, neurologists may also find usage of Lemtrada as a form of induction therapy. In approving a broad label for Lemtrada, the European Commission has at least opened the door for potential use across the MS treatment algorithm.



In addition to weighing up the efficacy and safety considerations of Lemtrada, a key factor in shaping uptake of Sanofi's product will likely be how the therapy is administered and how patients are subsequently monitored. The drug is administered initially daily (for about 7 hours) over a period of 5 days and then daily for a period of 3 days a year later. KOLs have noted that while this offers a certain level of convenience, monthly monitoring for certain patients, plus the logistics associated with administration taking place in a specialist setting, may preclude some usage of the product.



With the ABCR (Avonex, Betaseron, Copaxone and Rebif) therapies heavily entrenched and new oral therapies (Gilenya, Aubagio and Tecfidera – yet to launch in Europe) providing comparable efficacy with greater convenience, there is some suggestion among analysts that Lemtrada could compete quite closely with Biogen Idec's Tysabri. The latter represents another MS therapy that is recognised as being one of – if not the most – efficacious treatments available, but for which usage is limited by its side-effect profile. Biogen Idec has sought to improve the commercial opportunity for Tysabri via use of JVC testing, which is designed to limit the chance of patients using the drug developing PML.


Puchase Reasons


This week's Physician Views poll will ask neurologists based in the 5EU (France, Germany, Italy, Spain and the UK):


  • To what type of relapsing remitting MS patients they would feel comfortable prescribing Lemtrada to?

  • Based on current available therapies – which drug they would most likely switch patients to Lemtrada from?

  • How they assess the convenience of Lemtrada's administration and monitoring requirements?

  • To what percentage of all MS patients they anticipate prescribing Lemtrada to in 2 years time?

  • By what percentage they estimate that their use of Tysabri has changed since JCV testing was introduced?
  • Table of Contents
    for Physician Views: Sanofi secures EU approval for its multiple sclerosis treatment Lemtrada – how will neurologists use it? [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    66 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: Sanofi secures EU approval for its multiple sclerosis treatment Lemtrada – how will neurologists use it? [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...